

NOTE: This order is nonprecedential.

**United States Court of Appeals
for the Federal Circuit**

ABBVIE BIOTECHNOLOGY, LTD.,
Appellant

v.

UNITED STATES,
Intervenor

2017-2304, -2305, -2306

Appeals from the United States Patent and Trade-
mark Office, Patent Trial and Appeal Board in Nos.
IPR2016-00172, IPR2016-00188, and IPR2016-00189.

ABBVIE BIOTECHNOLOGY, LTD.,
Appellant

v.

**BOEHRINGER INGELHEIM INTERNATIONAL
GMBH, BOEHRINGER INGELHEIM
PHARMACEUTICALS, INC.,**
Appellees

UNITED STATES,
Intervenor

2017-2362, -2363

Appeals from the United States Patent and Trademark Office, Patent Trial and Appeal Board in Nos. IPR2016-00408 and IPR2016-00409.

ON MOTION

ORDER

Coherus BioSciences, Inc. moves unopposed to withdraw as a party to Appeal Nos. 2017-2304, -2305, -2306.

Upon consideration thereof,

IT IS ORDERED THAT:

(1) The motion to withdraw is granted. The revised official caption and short caption are reflected in this order.

(2) The Director of the United States Patent and Trademark Office is directed to inform this court within 30 days of the date of this order whether he will participate in these appeals.

(3) If the Director elects to participate, his brief and the United States' intervenor brief are due within 40 days of notification of the Director's election. To the extent the Director or the United States relies on portions of the record that are not already contained in the joint appendix, they must submit a separate appendix containing those portions of the record at the time they file their respective brief. AbbVie Biotechnology, Ltd. may file its reply brief within 14 days of the later of the date of filing of the Director's brief and the United States' brief.

ABBVIE BIOTECHNOLOGY, LTD. v. US

3

(4) If the Director elects not to participate, the United States' intervenor brief is due within 14 days of the Director's notice of non-participation. To the extent the United States relies on portions of the record that are not already contained in the joint appendix, it must submit a separate appendix containing those portions of the record at the time it files its brief. AbbVie Biotechnology may file its reply brief within 14 days of the date of filing of the United States' brief.

(5) A copy of this order shall be transmitted to the merits panel assigned to these appeals.

FOR THE COURT

Jan 31, 2019

Date

/s/ Peter R. Marksteiner

Peter R. Marksteiner

Clerk of Court

s25